Viral Hepatitis

The newly launched Homelessness and Infectious Disease Questions Ask a Question (AAQ) desk assists homeless assistance providers, Continuums of Care (CoCs), and other partners with questions about preventing, mitigating, and responding to infectious diseases impacting people experiencing homelessness in their community. The AAQ desk is staffed by Technical Assistance (TA) providers from HUD's disaster response team who are well-versed in promising and emerging practices for infectious disease planning, mitigation, and response in homeless response systems.

The Unitaid-funded LONGEVITY project aims to develop long-acting formulations for malaria and latent tuberculosis (TB) prevention and a single-injection cure for hepatitis C virus (HCV) for low- and middle-income countries, as these diseases disproportionately affect children, poor and marginalized communities, people who use drugs, and people living with HIV.

Although hepatitis B is preventable and treatable, there is still no cure for this disease. In addition to the devastating toll on patients and their families, ignoring hepatitis B costs the U.S. an estimated $4 billion per year in medical costs. Yet, the NIH will spend only $66 million in FY 2021 on hepatitis B research. Read more in this fact sheet.

This research discusses how PrEP was approved for HIV prevention in the US in 2012; uptake has been slow. Black and Hispanic people have higher rates of new HIV diagnoses than White non-Hispanic people in the US. We describe the inequitable use of PrEP by race within US regions from 2012-2021.

The Viral Hepatitis National Progress Report provides information on progress in the implementation of recommended interventions and the impact these interventions are having on prevention of viral hepatitis transmission, disease, and associated mortality.

This report discusses that national pharmacy claims data for 2014–2020, 843 329 persons were treated for hepatitis C at least once. The proportion treated increased annually among persons aged <40 years, insured by Medicaid, and treated by primary care providers. Monitoring hepatitis C treatment is essential to identify barriers to treatment access.

B Heppy is a podcast aimed to inform and help individuals living with hepatitis B through discussing various topics related to hepatitis B.

The #justB storytelling campaign aims to raise the profile of hepatitis B as an urgent public health priority and helps put a human face on this serious disease by sharing stories of real people living with or affected by hepatitis B. The goals of the campaign are to increase awareness and advocacy; decrease stigma and discrimination; and promote testing, vaccination, linkage to care, and treatment to help save lives. The #justB storytelling campaign is a program of the Hepatitis B Foundation in collaboration with StoryCenter and AAPCHO.

The resources presented here are based on data obtained from the Hepatitis B Foundation patient engagement survey in 2020. The survey was an anonymous and online and was offered globally for individuals living with chronic hepatitis B (CHB) and aged 18 years old and older. It received 1,707 responses from people living in 100 countries around the globe.

Harm Reduction Hacks is the product of a series of 38 qualitative conversations with harm reduction leaders representing every region of the US that took place in the Fall of 2020 and the Spring of 2021.